AfroCentric reports profit boost from drug deliveries

Group profit rose about a fifth in the year to end-June, with the company’s pharmacy delivery businesses faring well amid Covid-19

WATCH: How Aspen whittled down its debt pile

Business Day TV spoke to Aspen CEO Stephan Saad about the group’s full-year results

Aspen on the hunt for acquisitions

Emerging markets targeted for growth after disposals slash pharmaceutical giant’s debt

Aspen holds on to dividend over coronavirus uncertainty

The drugs maker slashed its debt by more than a third over an 18-month period

Labat eyes Eastern Cape cannabis operation

The acquisition of the licensed cultivation operation in the Eastern Cape comes as the group seeks to grow its presence in the cannabis market

Aspen sells European thrombosis business to Mylan

The proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says

Hospital occupancy lifts as lockdown eases, Life Healthcare says

Revenue in April was 40% lower than the previous year while it had increased on a monthly basis

Aspen raises dividend hopes as it slashes debt and boosts cash flow

Among the winners during the Covid-19 pandemic, the company cuts debt to within its target range and delivers strong operational cash flow

Adcock Ingram and peers call for medicine price increase

The company says the weak rand is squeezing its margins

Adcock Ingram holds on to dividend amid Covid-19 uncertainty

The group’s revenue in the year to end-June improved, but faced pandemic-related costs

J&J to spend $6.5bn on buying autoimmune-disease drugmaker Momenta

The deal is the latest sign that drug firms are seeking ways to bulk up even as the coronavirus pandemic upends other businesses

Galapagos shares plunge 33% after FDA rejects arthritis drug

The FDA is concerned about the benefit and risk profile of the treatment, filgotinib, and has asked for more data before completing its review

Sanofi buys US biotech company Principia for $3.4bn

Principia shares climb 11% after the French drugmaker announces the all-cash offer that will see it take full control

Q&A: What Covid-19 has taught Discovery Life

Protective value of a healthy lifestyle confirms Vitality model, says deputy CEO Gareth Friedlander

Thermo Fisher’s $12bn bid for Qiagen collapses

Revolt by investors puts an end to one of the biggest deals in the health sector in 2020

Bausch to make eye care unit separate listed company

Bausch + Lomb, bought in 2013, is a solid source of revenue, with Bausch US shares rising 28% after the news

Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.